Medscape
The US Food and Drug Administration (FDA) has approved single-agent darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals, Inc.) for the treatment of metastatic castration–sensitive prostate cancer (mCSPC). Darolutamide, an androgen receptor inhibitor, was previously approved in combination with docetaxel chemotherapy for mCSPC. The new single-agent approval is based on safety and survival outcomes in the randomized…
Read More
Darolutamide Now Approved as Single Agent for MCSPC
Yuri Buresh
07:20
The US Food and Drug Administration (FDA) has approved single-agent darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals, Inc.) for the treatment of metastatic castration–sensitive prostate cancer (mCSPC). Darolutamide, an androgen receptor inhibitor, was previously approved in combination with docetaxel chemotherapy for mCSPC. The new single-agent approval is based on safety and survival outcomes in the randomized…
